Alnylam Receives CHMP Positive Opinion of Vutrisiran for hATTR Amyloidosis in Adult Patients with Stage 1 or 2 Polyneuropathy
Shots:
- The EMA’s CHMP has adopted a positive opinion recommending approval of vutrisiran for hATTR amyloidosis in adult patients with stage 1 or 2 polyneuropathy. The EC's decision is expected in Sept 2022
- The opinion was based on the 18mos. results from the P-III (HELIOS-A) study evaluating vutrisiran in a ratio (3:1) in 164 patients at 57 sites in 22 countries. The trial met the 1EPs & 2EPs of study at 9 & 18mos. & showed the reversal in neuropathy impairment along with encouraging safety & tolerability profile
- Vutrisiran is under ANVISA & PMDA review. If vutrisiran is approved by EC, it will be commercialized under the brand name Amvuttra as 1st treatment option to demonstrate reversal in neuropathy impairment with SC administration
Ref: Bussinesswire | Image: Alnylam
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
